Managing the transition: switching bioanalytical laboratories during a clinical trial – a sponsor’s perspective

ABSTRACT

Bioanalytical (BA) data are foundational to clinical trial integrity and regulatory success. Yet, circumstances such as regulatory noncompliance, operational disruptions, resource limitations, or evolving analytical needs can necessitate a BA laboratory transition during a clinical trial. Through the lens of a real-world case study and supported by broader industry experience, this manuscript explores the operational, scientific, and regulatory challenges of BA laboratory transitions. We examine four potential scenarios that trigger such changes, the risks to data continuity and compliance, and the significant implications for sponsors. The manuscript outlines actionable, multidisciplinary strategies for managing transitions: from vendor qualification and project planning to Corrective and Preventive Action (CAPA) implementation, method transfer, and ongoing performance assessment. When guided by early risk recognition, transparent communication, and organizational learning, laboratory transitions though challenging, can be successfully navigated to protect trial outcomes and strengthen the resilience of clinical programs.

1. Introduction

Clinical trials evaluate the safety and efficacy of new drug therapies, diagnostics, and medical devices in humans. Across the spectrum of drug development spanning Phase I, II, III, and IV trials, each stage represents a point where a drug’s progression is assessed [1]. At the core of these trials is the generation and interpretation of Bioanalytical (BA) data, which are indispensable for evaluating pharmacokinetic (PK), pharmacodynamic (PD), biomarker, and immunogenicity assessments [2–4]. BA data underpin dose selection, safety evaluation and regulatory submissions. The reliability and integrity of BA data are fundamental for credible clinical trial outcomes, supporting regulatory submissions and treatment guidance [5]. Global regulatory frameworks (International Council for Harmonisation (ICH M10), U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA)) shape expectations for validation, data integrity, and inspection readiness in bioanalysis [6–8].

Clinical trials frequently span multiple geographies and these studies involve collecting and analyzing large numbers of biological samples, which are processed at qualified BA laboratories. BA Contract Research Organizations (CRO) develop and validate BA methods, process large sample volumes and ensure compliance for the drug approval [9]. When selecting a CRO for early method development, it is critical to consider many factors. Key selection factors include scientific capability, modality expertise, capacity (lead time), past performance (if applicable), data turnaround timelines, throughput, regulatory adherence, sustained study support, and potential partnership [10]. Despite careful planning, unforeseen circumstances can necessitate BA method transition away from a CRO posing substantial risks to data deliveries and creating logistical hurdles in sample and method transfer [11].

Acknowledging the practical risks, we present a real-world case study, analyze common transition scenarios, and outline management practices to successfully navigate such transitions.

2. Scenarios resulting in laboratory transition

Methodological deviations or data inconsistencies are a few challenges that can arise over the course of a clinical trial. These challenges can disrupt data integrity and trial progression [12]. Regulatory audits or internal Quality Assurance (QA) assessments may identify issues such as noncompliance with regulatory standards [13], incomplete documentation, improper handling of samples, and deviations from validated methods. Such problems may compromise data credibility and necessitate a mid-study lab transition.

2.1. Real-world case study

Following the acquisition of an asset as part of a strategic portfolio expansion, the sponsor inherited an ongoing BA partnership with a third-party, referred to here as CRO-1. This laboratory, primarily a Clinical Laboratory Improvement Amendments (CLIA)-certified facility, had not been the sponsor’s preferred partner or pre-qualified under GxP standards. Within one month of assuming oversight responsibility, the sponsor’s bioanalysis team conducted a detailed review of CRO-1’s operations and identified several concerns regarding its ability to support GxP-regulated clinical studies. Notably, CRO-1 operated as a CLIA laboratory and lacked relevant GxP (Good Laboratory Practice (GLP)/Good Clinical Practice (GCP)) certifications. Subsequently, the methodologies, data management, and quality assurance practices were not aligned with global regulatory expectations for clinical research.

A structured data review of clinical study data and sample management processes revealed severe integrity issues. Results were reported for samples not logged as received; shipment manifests and tracking were inconsistent. There were recurring mismatches between sample shipment manifests, records from the central lab, and samples received at CRO-1. Additionally, barcoded sample labels were inconsistent, differing between the central lab, CRO-1’s records, and subsequent documentation used for transfer to an alternate lab, referred to here as CRO-2. These inconsistencies compromised the traceability and chain of custody of clinical samples. Shipping delays were also noted throughout the process. Uncommunicated shipping delays created uncertainty in sample integrity. CRO‑1’s delayed responses hindered reconciliation. Lastly, procedural deficiencies also existed. The processes for reviewing and archiving data were limited to processed results. Raw data were either unavailable, missing, or not subjected to GxP-compliant verification. These included instances where data were generated for samples that, according to sample management logs, were never received or accounted for by the CRO-1.

Given these findings, the sponsor initiated immediate action, and a comprehensive on-site data audit was performed. The review sought to determine the fitness of these data to support regulatory submissions but concluded that none met the required standards for reliability or traceability. In response to the audit outcomes and risk assessment, a decision was made to transfer all critical BA activities and methods from CRO-1 to CRO-2, a lab with robust GxP compliance. However, during method transfer and efforts to establish data continuity, CRO-1 refused to participate in cross-validation activities. This lack of cooperation further reinforced concerns regarding its noncompliance and the appropriateness of the transition decision to a better-qualified laboratory. To ensure continuity, CRO-2 was selected for its legacy project knowledge. Since the primary and several backups’ samples had already been analyzed and exhausted at CRO-1, CRO-2 had to rely on remaining backup specimens, some of which presented barcode discrepancies requiring reconciliation before analysis. Given the time required for method transfer and validation at CRO-2, sample stability became a significant concern, and a subset of specimens was ultimately lost due to stability lapses. All relevant methods were validated and samples analyzed at CRO-2.

Ultimately, none of the data generated by CRO-1 for the clinical study was used in regulatory submissions to ensure data consistency and quality. The case underscores the need for rigorous due diligence and cooperative, transparent method transfer.

This case study underscores the cascade of challenges that can arise when a laboratory transition becomes necessary during a clinical trial. However, the challenges encountered are not unique. Building on this case study, four recurring scenarios are seen in practice that can require a mid-study transition between BA laboratories. Understanding these scenarios in light of real-world experiences equips sponsors to proactively address and mitigate disruption. The cascade of challenges, decisions, and required remediation steps undertaken in this real-world transition, from initial oversight to successful transition to CRO-2, is schematically summarized in Figure 1.

Figure 1.

A schematic flow diagram illustrating the transition strategy, based on the real-world case study, for migrating bioanalytical support from a non-GxP-compliant contract research organization (CRO-1) to a fully qualified, GxP-compliant facility (CRO-2) following the acquisition.

2.2. Scenario 1: laboratory quality control failures

In accordance with regulatory compliance expectations, including FDA and EMA data integrity principles (ALCOA+, chain-of-custody, audit trails) laboratories must maintain rigorous quality control (QC) systems to ensure analytical reliability [14,15]. When these standards are not consistently met, sponsors can face serious issues originating from inadequate QC practices, deviations from regulatory standards [16], or methodological deficiencies at the original laboratory [17]. Measurement errors, inconsistent results, or recurring procedural deviations often due to poorly calibrated equipment, inadequate staff training [4], or lapses in Standard Operating Procedure (SOP) adherence can undermine analytical integrity [16,17]. As the case study revealed, hidden weaknesses frequently come to light during audits, where sample and data traceability were compromised. Systemic issues include incomplete validation packages, inadequate change control, ineffective second person review, and deficient instrument lifecycle management. Risk signatures associated with these gaps include elevated out of specification (OOS) and out of trend (OOT) rates, high repeat analysis frequency, and discordant incurred sample reanalysis (ISR) outcomes. Data integrity considerations commonly involve traceability of sample custody, metadata completeness, and audit trail continuity when QC execution varies.

2.3. Scenario 2: post-merger integration

Aligned to FDA/EM expectations for governance consistency and raw data accessibility across site, corporate reorganizations such as mergers, acquisitions, or licensing agreements often expose operational or compliance issues in inherited laboratories. Prompt and thorough due diligence is critical, as post-integration audits may reveal shortcomings in compliance or data management. Typical features include non‑aligned SOP hierarchies, divergent validation philosophies, and fragmented Laboratory Information Management Systems (LIMS)/Electronic Lab Notebook (ELN) implementations with incomplete audit trails and variable metadata standards, resulting in heterogeneous data lineage and traceability profiles across sites. Documentation practices and version control may differ, with gaps in role‑based access control and archival/backup integrity affecting retrieval fidelity [11].

2.4. Scenario 3: scaling capacity

Given FDA/EMA scrutiny of fluctuations in assay performance and adverse OOS/OOT trends [6,8], clinical programs may unexpectedly expand due to interim findings, new scientific demands, or regulatory requirements [18]. These demands can outstrip a laboratory’s technical or operational capacity. Signals include prolonged cycle times, backlog accumulation, rising batch failure rates, and turnaround variability tied to single‑point dependencies (specialist personnel, unique instrument platforms, or critical reagent supply) [18]. Scientific complexity, low-abundance targets, multiplexed panels, and high throughput PK/ADA sample analysis can stress robustness, and impact ISR cadence and review timeliness.

2.5. Scenario 4: operational disruptions

In accordance with FDA/EMA expectations to preserve traceability and reconstruct custody/audit trails during disruptions [15,19] events such as facility closures, accidents, staffing shortages, or crises like pandemics [20,21] can halt laboratory operations, sometimes without adequate time to recover. The unpredictability and scale of such challenges often render CAPA impractical for immediate resolution. Characteristics include immediate throughput collapse, supply‑chain interruptions for critical consumables/reagents, restricted facility access, and loss of qualified personnel for critical steps. Environmental or infrastructure instability (HVAC/utilities) may affect instrument suitability and the validated state, with downstream effects on chain‑of‑custody execution, metadata completeness, and audit‑trail continuity under emergency procedures.

In each scenario, CAPA is the initial remedy, an industry standard for addressing emerging laboratory challenges. However, transition is warranted when issues persist, or data integrity cannot be assured. These experiences demonstrate that while not every challenge will lead to a lab transition, sponsors must be equipped with robust frameworks to intervene early and act decisively when required.

3. Implications of laboratory transition

Transitioning laboratories has broad operational, scientific, and regulatory effects. As highlighted in the case study, routine lapses can escalate into systemic failure, affecting major milestones. Method transfer and validation can introduce non comparable results owing to differences in platforms or staff expertise, sometimes only evident at transfer [22,23]. Bridging studies, or cross-validation, are often required to confirm data comparability and integrity [24,25]. The resulting burden can be substantial, delaying timelines, interim analyses, and potentially trial completion [20,26,27].

Regulatory agencies may require a transparent justification for any transition, especially when gaps or noncompliance issues are identified. Insufficient evidence of data continuity can trigger reanalysis requests, data rejection, or regulatory delays [7,18]. From vendor qualification [28] to secure movement of biospecimens, each facet of the move must be managed in a way that preserves chain-of-custody and documentation. Loss of key samples, particularly from rare populations, can irreversibly undermine a trial. Financially, direct and indirect costs (from contract remediation to lost opportunity) further underline the need for careful planning.

3.1. Regulatory authority considerations

Laboratory transitions carry regulatory implications that extend beyond operational logistics. Authorities expect transparent justification for the switch, comprehensive documentation of data integrity controls, and evidence that analytical performance is comparable post-transfer. Sponsors should assess and disclose impacts on PK/PD, biomarker, and immunogenicity endpoints, identifying datasets excluded, reanalyzed, or bridged and explain implications for interim analyses and trial conclusions. Aligned with FDA Bioanalytical Method Validation Guidance [6], ICH M10 [7], and EMA Guideline on Bioanalytical Method Validation [8], sponsors should demonstrate comparability and maintain inspection‑ready data integrity artifacts, tracking Key Performance Indicators (KPIs)/Quality Tolerance Limits (QTLs), and harmonizing regulatory expectations (FDA/EMA/PMDA). These steps reduce the likelihood of data rejection, requests for reanalysis, or submission delays, and position the program to withstand regulatory scrutiny.

These realities guide our practical, stepwise framework designed to help sponsors anticipate, manage, and recover from laboratory transitions while safeguarding data and operational continuity.

4. Strategies for managing laboratory transition

Successful BA transitions require more than technical skill; they demand proactive, coordinated action (Figure 2). The following strategies shaped by the case study experience and broader industry learning enable sponsors to anticipate, plan, and execute transitions while safeguarding data quality, timelines, and compliance [3,29].

Figure 2.

Schematic of vendor selection and BA laboratory network in clinical trials.

4.1. Vendor selection, auditing, and qualification

Robust vendor selection underpins long-term reliability. In the case study, lack of robust vetting by the original sponsor at the outset of their studies exposed the new sponsor to data integrity failures. By evaluating each prospective CRO’s technical capabilities, regulatory record, and history of quality performance, sponsors can preempt many downstream risks [9,28]. In-depth onsite or remote audits should scrutinize data traceability, SOP compliance, staff qualifications, and equipment calibration [12,16,30,31]. Developing relationships with multiple pre-qualified CROs provides a safety net for swift transitions.

4.1.1. Potential action

Adopt standardized, weighted checklists to direct vendor selection, and involve both QA and legal early for risk mitigation. Begin documentation at first contact; continuously update the roster of qualified CROs, drawing on audit outcomes and performance reviews [28].

4.2. Project teams and timeline planning

A clear lesson from our experience is that transitions cannot be siloed efforts. Smooth transitions hinge on engaged, multidisciplinary project teams. Missed deadlines, communication gaps, and misaligned priorities highlight the consequences of inadequate coordination. Early assembly of a cross-functional team spanning project management, clinical operations, BA operations, regulatory affairs, QA, and legal ensures comprehensive coverage [31]. Timeline planning should be realistic and resilient, accounting for complex handovers and potential setbacks, with scenario drills used to reveal overlooked vulnerabilities before a real transition hits.

4.2.1. Potential action

Mandate regular meetings across teams, support collaboration with real-time tools, and embed contingency exercises so teams can respond swiftly in a crisis.

4.3. Ongoing monitoring, communication, and feedback

Resilient laboratory transitions are maintained through an unwavering commitment to monitoring and open communication. In the case study, failure to recognize and address emerging issues could have led to snowballing delays and uncertainty. Sponsors should view monitoring as a continuous process, rather than a post-facto audit. Periodic (and sometimes surprise) audits support real-time course correction by revealing deviations in data quality, adherence to timelines, or regulatory standards [3,31]. Maintaining effective communication, both within sponsor teams and with laboratory partners, builds a shared sense of accountability and allows for rapid response when obstacles arise. Structured feedback loops inviting direct input from stakeholders at every level enable sponsors to refine approaches and instill an ongoing culture of process improvement. Early backup lab arrangements add confidence in high-stakes settings [10,28].

4.3.1. Potential action

Host periodic governance meetings to systematically review KPIs), QTLs, and operational performance [28]. Utilize data dashboards for visualization and early issue detection. Hold debriefing sessions after each transition or major milestone, using lessons learned to update SOPs and refine risk management protocols [32]. Regularly test communication and escalation pathways to prevent breakdowns when time is critical.

4.4. Quality issues and CAPA implementation

The case study demonstrated that a CRO having superficial CAPA without ownership or follow-through can lead to recurring failures and ultimately force transition. Managing laboratory quality issues requires robust oversight anchored in a well-developed CAPA framework with additional measures (Figure 3). Effective CAPA is built on precise root cause analysis, clear accountability, and enforceable timelines. Collaborating transparently with CRO partners, and involving third-party experts when appropriate, strengthens root-cause assessment and fosters sustained solutions [16,28]. Ongoing SOP reviews, regular calibration and validation of equipment, and regularly updated training are crucial for consistency and regulatory alignment. Establishing QTLs and reviewing KPIs make oversight dynamic. In instances of repeated failure, or when high-impact CAPA is required, independent reassessment and re-auditing verifies effectiveness [12,16].

Figure 3.

Framework for vendor management and continuous oversight of BA laboratory in clinical trials.

4.4.1. Potential action

Assign clear owners and measurable outcomes for each CAPA plan [28]. Develop follow-up schedules, involve cross-functional teams in remediation, and hold CAPA “post-mortem” sessions capturing lessons learned. Where complex issues threaten trial continuity, engage external experts to validate findings and oversight. Ensure all corrective actions and documentation are maintained for regulatory inspection and internal learning.

4.5. Method transfer, validation, and regulatory engagement

Delays and incompatibilities during method transfer, as seen in the case study, are a leading cause of lost time and regulatory friction. Method transfer and validation are central to any successful laboratory transition. In the case study, backlog and misalignment during sample and method handoffs resulted in delays and potential regulatory scrutiny in the future. From the outset, sponsors should standardize transfer protocols specifying assay performance parameters, together with the associated operational enablers (instrument configuration/qualification and SOP‑controlled procedures) to maintain assay fidelity [24,25,33]. Early, hands-on engagement between scientific staff at both laboratories smooths the transfer of expertise and minimizes inconsistencies. When laboratories use different platforms or techniques, structured bridging studies and cross-validation must be planned to demonstrate continuity and integrity [23,24]. Transparent, timely communication with regulatory authorities helps avoid surprises, ensuring alignment on what constitutes acceptable validation, documentation, and clinical impact assessment [33]. Logistics integral to method application, such as temperature‑controlled shipment and documented custody for transfer materials should be defined within the transfer plan to protect method performance during transition [3,33].

Regulatory engagement should be proactive and embedded in every laboratory transition plan. Sponsors should document a clear, risk-based transition rationale (root-cause analysis, CAPA attempts, and escalation criteria) and notify authorities when changes may affect data integrity, endpoints, or timelines. Inspection readiness hinges on demonstrable chain-of-custody, raw data accessibility, and auditable decision trails supported by vendor qualification files, audit reports, CAPA plans with effectiveness verification, training records, and equipment qualification/calibration. Method transfer must be supported by bridging/cross-validation evidence covering accuracy/precision, bias, matrix effects, stability, and comparability of controls/QCs, aligned to ICH M10 and internal GCP BA expectations. Documentation and bridging should reflect expectations for accuracy/precision, selectivity, stability, dilution integrity, and ISR, consistent with regulatory guidance [6–8]. Define and monitor QTLs and KPIs (error rates, reanalysis rates, timeliness) and summarize detection and mitigation of issues. Segregate non-usable data, outline revalidation/reanalysis, and compile a transition dossier (communications log, SOP updates, bridging results) to demonstrate control throughout the change.

4.5.1. Potential action

Implement standardized transfer templates and embed staff participation in both sending and receiving laboratories. Design robust methods upfront to mitigate method transfer risk. Use digital chain-of-custody tracking and build sufficient buffers for unexpected issues. Notify regulators early with a concise transition rationale and evidence of equivalency and retain auditable records of all communications [33].

4.6. Financial planning and oversight

The case study illustrated that a delayed or under-funded transition can compound disruption; foresight in budgeting and contract design is invaluable. Transitions carry a high financial burden, sometimes direct (qualification, validation, and shipping) and sometimes indirect (project delays, duplicate efforts, or delayed approvals) [20,26,27]. The urgency in the case study highlighted how unplanned transitions can place strain on trial budgets and timelines. Effective financial planning begins with fully itemizing and anticipating both fixed and variable costs and allocating contingency funds to absorb surprises. Each contract should clearly define scope, pricing, and deliverable timelines, minimizing the risk of ambiguity or post-hoc negotiation. Tracking transition-related expenditure independently from overall trial costs allows for clearer oversight, benchmarking, and post-transition lessons for future projects [10,28].

4.6.1. Potential action

Segregate and monitor all costs tied to transition activities. Routinely perform cost-benefit analyses for backup CROs or parallel validation, especially in pivotal trials. After each transition, update contracting language to reflect actual challenges encountered, and formalize this knowledge for future budget cycles.

4.7. Ongoing assessment and improvement

No transition is truly complete without organizational learning. Ongoing assessment and knowledge sharing drive improvement. Post‑transition reviews and feedback reveal hidden inefficiencies. The case study reveals how post-transition review and pulling together feedback from all teams can reveal hidden inefficiencies or risks that might otherwise persist. Closely analyzing process data and project outcomes and using these insights to update SOPs and internal training, embeds learning across the organization. Sharing key lessons, both internally and across the industry helps elevate best practices and drives transition excellence [32].

4.7.1. Potential action

Schedule post-transition evaluation to assess process effectiveness and identify improvement opportunities. Actively promote knowledge exchange and incorporate concrete learnings into SOPs and future transition strategies, keeping teams on the path of continual improvement.

5. Conclusion

Transitions between BA laboratories, particularly in the midst of a clinical trial, represent inflection points in drug development, often triggered by regulatory lapses, capacity shortfalls, or fundamental quality concerns. Transitions are challenging but enable resilience and proactive culture.

Success relies on anticipating challenges through robust vendor selection, empowered project teams, and dynamic quality oversight. Standardizing CAPA, strong communication, and comprehensive documentation, and timely regulatory engagement prepares teams to navigate transitions without jeopardizing trial integrity or program timelines. Each strategy outlined here, drawn from real experience, underscores the value of structured preparation and continuous assessment.

Investments in internal capabilities, such as enhanced automation or informatics, can further reduce reliance on external partners, broadening the toolkit available when a transition is unavoidable. Moreover, a strong safeguard against laboratory transitions is rigorous upfront vetting and selection of an appropriate partner laboratory, thereby markedly reducing the likelihood that a transfer will be required. However, transitions are rarely one-size-fits-all. Effective risk management depends on project complexity, therapeutic area, and regulatory expectations. Our guidance is therefore intentionally practical and adaptable, rooted in collective learning as much as direct observation. Ultimately, by combining strategic planning, operational discipline, and an ongoing commitment to learning, sponsors can not only weather the complexity of laboratory transitions but emerge stronger, delivering reliable data, advancing clinical programs, and ensuring new therapies reach patients both efficiently and safely.

6. Future perspective

Based on the authors' experience, over the next 5–10 years, bioanalytical transitions will shift from reactive fixes to proactive, digital capabilities embedded in sponsor quality systems. Digitization (eSource, immutable chain-of-custody, interoperable LIMS/ELN) will close traceability gaps and enable near real-time risk detection. AI-analytics will forecast nonconformances, triggering automated CAPA and standardized transitions. Also of benefit is standardization of portable validation packages, templated transfer dossiers, and consensus cross-validation criteria, compressing timelines. Resilience will strengthen via multi-site, pre-qualified CRO networks with mirrored platforms, cloud-hosted SOPs, and shared training credentials, enabling parallel testing and rapid failover. Rising multifunctional biologics complexity will result in higher complexities of method transfer and data models, coupling fit-for-purpose validation with model-informed decisions. The outcome is engineered adaptability, where transparent governance, predictive oversight, and interoperable data make continuity the default and embed learning into living quality frameworks.

Funding Statement

This paper was not funded.

Article highlight

Clinical trials generate large sample volumes across geographies, analyzed by qualified BA CROs under GxP expectations. CRO selection should balance turnaround, throughput, regulatory adherence, longitudinal support, and partnership potential. Despite planning, method transfers between CROs during and ongoing study may be required, risking continuity and logistics.

Scenarios resulting in laboratory transition

• Scenario 1 – QC failures: Issues include measurement errors, OOS/OOT rates, ISR discordance, incomplete validation, and instrument lifecycle gaps; regulatory focus on ALCOA+, chain of custody, and validated state evidence.

• Scenario 2 – Post-merger integration: Heterogeneous SOPs, validation interpretations, LIMS/ELN audit trails, metadata standards, and governance; regulatory focus on consistent raw data access and validated state across sites.

• Scenario 3 – Scaling capacity: Demand outstrips capability; indicators include backlog, cycle time variability, batch failure, single-point dependencies, ISR cadence impacts; regulatory focus on sustained validated state variability and adverse OOS/OOT trends.

• Scenario 4 – Operational disruptions: Closures, accidents, shortages, crises cause throughput collapse, supply interruptions, and infrastructure instability; regulatory focus on maintaining traceability, custody, and audit trail during emergencies.

Implications of laboratory transition

• Method transfer/validation can introduce variability; bridging/cross-validation adds workload and may delay milestones. Loss of key samples and documentation gaps threaten interpretability. Direct/indirect costs necessitate proactive planning.

• Regulatory Authority Considerations: Transparent rationale, comprehensive integrity controls, maintained validated state/performance. Limit risk via inspection ready records, KPI/QTL tracking, and harmonized global expectations.

Strategies for managing laboratory transition

• Vendor selection/qualification: Robust, audit-backed, maintain prequalified options.

• Project teams/planning: Multidisciplinary governance, realistic timelines, scenario drills.

• Monitoring/communication: Continuous audits, clear cadences, feedback loops, backup labs.

• Quality/CAPA: Root cause rigor, accountable remediation, QTL/KPI oversight, independent verification.

• Method transfer/validation: Standardized templates, critical assay parameters, bridging/cross validation, early regulatory engagement; digital chain of custody and controlled logistics.

• Financial oversight: Segregated tracking, contingency budgeting, updated contracting.

• Ongoing improvement: Post-transition reviews, SOP/training updates, institutionalized lessons.

Conclusion

• Transitions are challenging but enable resilience and a proactive quality culture.

• Strategic planning, disciplined operations, standardized CAPA, and timely regulatory engagement safeguard integrity and timelines, strengthening programs and supporting safe, efficient delivery of new therapies.

Future perspective

• Digital shift, predictive quality, standardization, multifunctional biologics complexity, and engineered adaptability define the future of bioanalytical transitions.

Author contributions

Ketaki Deshpande made significant contribution to the work reported. Mark Ware, Mark Dysinger, Ming Li and Mira Hong have substantially revised or critically reviewed the article.

Disclosure statement

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript

Reviewer disclosures

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.